Gradual dosing of Lilly drug for Alzheimer’s disease reduces risk of brain swelling
Starting a more gradual dosing schedule for Eli Lilly’s Alzheimer’s disease drug Kisunla reduces the percentage of patients suffering from potentially serious brain swelling, according to interim results from a late-stage study presented at a medical meeting Tuesday.
ENTRADAS POPULARES
Thousands left without power in Washington State
noviembre 21, 2024
Eight times as many children will face extreme heatwaves in 2050
noviembre 21, 2024
Elton John’s Tammy Faye to close on Broadway
noviembre 21, 2024
TRANSMISIÓN EN VIVO